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Background. Therapeutic ultrasound (US) is an electrophysical therapy that is commonly used by sports physiotherapists, but its mechanism 
of action is unclear. There is little evidence that US therapy is more effective than sham US therapy, and any clinical benefits may be due 
to a placebo effect. 
Objective. To investigate whether US has a specific effect that renders it effective in its own right, or whether its effect is placebo driven.
Methods. In a double-blind controlled trial, delayed-onset muscle soreness (DOMS) was experimentally induced in both bicep muscles 
of 15 females. Sham US was applied to one bicep (n=15 biceps) and pulsed active US to the other bicep (n=15 biceps) of each participant, 
48 and 72 h after induction of DOMS. Primary and secondary outcomes were pain reported on the McGill Pain Questionnaire (MPQ) and 
range of movement (ROM) (elbow extension) measured by goniometry, respectively. 
Results. Results showed significant improvements in pain and ROM over the intervention periods, but there was no difference between 
interventions.
Conclusion. US and sham US therapy improve pain equally when treating DOMS of the biceps in the context of a therapeutic encounter. 
This analgesic effect is placebo driven. Clinicians can influence the analgesic effect of US by managing the therapeutic context. Management 
of patients’ anxiety may also boost the analgesic effect of US.
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Therapeutic ultrasound (US) is an electrophysical 
therapy that is commonly used by sports 
physiotherapists, but its mechanism of action is 
unclear.[1] There is little evidence that US therapy is 
more effective than sham US therapy, and any clinical 
benefits may be due to a placebo effect.[2] 
The term ‘placebo effect’ is used when a treatment that is known to 
have no specific physiological efficacy produces a positive therapeutic 
outcome. It is heavily reliant on the context of treatment and on the 
patient’s expectation of benefit.[3] Physiotherapists enhance placebo 
value by using positive therapeutic relationships and educating their 
patients about the anticipated effects of treatment.[4]
Delayed-onset muscle soreness (DOMS) is pain or discomfort 
that develops in muscles after exercise that is unfamiliar.[5] DOMS 
is self-limiting and easily induced experimental setting. Clinical 
findings include muscular tenderness and loss of range of movement 
(ROM), flexibility and strength. Symptoms develop gradually and 
peak after 24 - 48 h, resolving within 72 h.[6] The efficacy of US in 
treatment of DOMS has been investigated by a few studies of poor 
methodological quality.[2]
Methods
This study investigated the effect of US in the treatment of DOMS, 
and was designed to explore whether US has a specific effect, or 
whether it works via a placebo effect. A double-blind controlled trial 
was designed to compare the effects of active US v. sham US on the 
symptoms of experimentally induced DOMS of the biceps muscle 
group. The primary outcome was pain, measured by the McGill 
Pain Questionnaire (MPQ);[7] the secondary outcome was elbow 
ROM, measured with a goniometer.[8] The study was conducted in 
accordance with the Declaration of Helsinki and approved by the 
institutional research ethics committee.
Participants and setting
Healthy female physiotherapy students at the University of Cape 
Town were invited to participate. Exclusion criteria were pre-
existing medical conditions for which US is contraindicated, pre-
existing upper limb discomfort or injury, prior experience of US 
treatment for DOMS or altered test results for skin hot/cold or sharp/
blunt sensations. Twenty undergraduate students, aged 18 - 25 years, 
volunteered. Participants were given an information sheet listing the 
symptoms of DOMS and the study procedures, and then given an 
opportunity to ask further questions before agreeing to participate. 
Participants were asked not to take pain medication, perform any 
strenuous exercise or change their diets during the course of the study. 
At the end of the study, participants were given information sheets 
detailing interventions that might help to clear remaining symptoms. 
Interventions and data collection were conducted at the physiotherapy 
practical teaching venue of the University of Cape Town. 
Outcome measures
The outcome measures were pain and elbow ROM. Pain was assessed 
using the MPQ, which has shown good validity and reliability in 
DOMS-related pain[9] after translation and across cultures.[7] Elbow 
ROM was measured using standardised goniometry, also shown 
to be valid and reliable by numerous authors. [9] Goniometry was 
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performed while participants sat with the 
upper arm supported. The goniometer’s 
stationary arm was aligned with the 
longitudinal axis of the humerus and the 
moving arm with the longitudinal axis of the 
forearm. One researcher (Assistant A) took 
all measurements.
Pilot study
A pilot study was performed to standardise 
the methods of DOMS induction and data 
collection. In the pilot study, an I-KON1011 
(Chattanooga Ltd, USA) isokinetic machine 
was used to induce DOMS, but this was 
found to be ineffective. It was replaced by 
the following eccentric exercise protocol 
described by Stay.[10] Participants performed 
concentric and eccentric bicep curls using a 
dumbbell. Participants performed four sets of 
10 repetitions (or to muscle failure) at 80% of 
their one-repetition maximum (1RM). This 
was followed by four sets of 10 repetitions (or to 
muscle failure) of eccentric contractions at 100% 
of their 1RM. During the eccentric contraction, 
participants were instructed to slowly lower 
the dumbbell from full elbow flexion to full 
extension over 5 s, with Assistant C returning 
the weight to the starting position. Participants 
rested for 1 min between each set. With the new 
protocol, pilot participants reported maximal 
symptoms 48 h after exercise. 
Procedure
The experimental procedure is illustrated in 
Fig. 1.
Baseline data collection (T0)
Baseline measures of pain and elbow ROM 
were recorded for both biceps (left and 
right) of each participant before DOMS was 
induced (T0).
Induction of DOMS (T0)
Before DOMS was induced, a researcher read 
a prepared script to the participants to remind 
them of the symptoms of DOMS. Participants 
were then asked to perform bilateral, resisted 
concentric and eccentric bicep curls according 
to the protocol previously described.[10] 
Following this exercise bout, participants 
were asked to return for US treatment at 
48 and 72 h. 
Ultrasound (T48 and T72)
US Sonoplus 190 machines were calibrated 
and used with an appropriate coupling gel. 
The same two researchers (Assistants B 
and C) administered all US interventions.
At 48 h (T48), a script explaining the upcoming 
procedure was read to the participants. Pain 
and ROM were measured by Assistant A. 
Machine A delivered active US at 1 Mhz, 
0.4 W/cm2, pulsed 1:4, for 7 min. Machine B 
delivered a sham dose (intensity set to 0 
W/ cm2) for the same time period. Assistant 
D set up the US machines behind a screen 
and all instrumentation was covered so that 
the researchers operating the US machines 
and all participants were blinded as to which 
machine delivered which dose. 
Assignment of machine to biceps was 
quasi-random. Assistant E allocated the first 
participant’s right arm to one intervention by 
coin toss, and subsequent participants’ arm 
allocations were alternated.
Both arms were treated concurrently (one 
with Machine B and one with Machine A). The 
same two researchers administered treatment 
with the same machines at 48 (T48) and 72 h 
(T72). This consistency was maintained to 
standardise treatment and minimise bias.
Data collection
Pain and ROM were re-assessed before and 
after each intervention session by a single 
researcher (Assistant A), who was blinded as to 
which arm received active or sham treatment.
Statistical analysis
A 30% reduction in pain was considered 
clinically significant.[11] A power calculation 
with p<0.05 suggested a sample of 15 partici-
pants (N=15 biceps per group) to detect this 
change, with a power of 0.86.
Data were recorded using Microsoft Excel 
(2003) and analysed using SPSS Statistics 
version 21 (IBM, USA). Kolmogorov-Smirnov 
tests found that the data were normally 
distributed. Repeated measures analyses of 
variance (ANOVA) with a priori comparisons 
were used, for both outcomes, to compare each 
time point with the preceding one. Statistical 
significance was set at p<0.05. Results were 
presented using means and standard deviations. 
Mauchly’s test was used to assess the assumption 
of sphericity. Where sphericity was violated, 
degrees of freedom were corrected using the 
Greenhouse-Geisser estimates of sphericity and 
the corrected value was reported. 
Results
Demographics
Twenty female students volunteered for the 
study. One was excluded because of recently 
DOMS   induced Intervention 1 Intervention 2
T48 T49 T72 T73T0
Time (h)
Fig. 1. The experimental procedure. (DOMS = delayed-onset muscle soreness.)
20 volunteers recruited
DOMS induced
Allocated to active US
– Received intervention
15 participants remaining
 (n=30 biceps)
– Analgesic use (n=2)
– Diabetes (n=1)
– Inadequate induction of DOMS (n=2)
Excluded (n=1)
Excluded (n=4)
– Analysed (n=15 biceps)
Allocated to sham US
– Received intervention
– Analysed (n=15 biceps)
Fig. 2. Breakdown and allocation of research volunteers. (DOMS = delayed-onset muscle soreness; 
US = ultrasound.)
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diagnosed diabetes. Two participants were 
excluded because DOMS was not adequately 
induced (they had no pain or loss of ROM 
48 h aft er the exercise bout), and a further 
two for using analgesics.
Th e fi nal sample comprised 15 participants: 
15 biceps in the experimental group and 15 in 
the control group (Fig. 2).
Eff ect of US v. sham US on DOMS symptoms 
Th e changes in pain over time are shown in 
Fig. 3. Repeated measures 2 (intervention: 
active or sham US) × 4 (T48, T49, T72, T73) 
ANOVA showed that the type of intervention 
had no eff ect on pain (p=0.884). However, pain 
diff ered over time (F(1.68, 23.53.)=6.94; p=0.006). 
Contrasts showed that pain decreased 
significantly from T48 to T49 (F(1, 14)=7.35; 
p=0.017), and from T72 to T73 (F(1, 14)=12.27; 
p=0.004), revealing that the two interventions 
were equally effective on both treatment 
occasions. Contrasts also showed that pain did 
not change between interventions from T49 to 
T72 (p=0.59). Th ere was no interaction eff ect 
between intervention and time. 
Th e changes in ROM over time are shown 
in Fig. 4. Repeated measures 2 (intervention) 
× 5 (T0, T48, T49, T72, T73) ANOVA showed that 
the type of intervention had no eff ect on ROM 
(p=0.198). However, ROM did change over 
time (F(2.32, 32.52)=18.91; p=0.0001). Contrasts 
showed that ROM diminished from baseline 
to T48 (F(1, 14)=87.68; p=0.0001), and then 
increased over the fi rst intervention period 
from T48 to T49 (F(1, 14)=11.32; p=0.005). ROM 
did not change over the second intervention 
period (p=0.09), or between interventions 
(p=0.67). There was significant interaction 
eff ect (F(4, 56)=2.91; p=0.030). Contrasts for this 
interaction were marginally signifi cant at one 
level: T49 v. T72 (F(1, 14)=4.66; p=0.049). Over this 
time period, ROM decreased in the active US 
group and increased in the sham US group. 
Discussion
Natural history or placebo eff ect?
This study used a double-blinded, within-
subject design to investigate the effi  cacy of 
sham v. active US interventions for decreasing 
pain related to DOMS of the biceps. 
Participants received each intervention twice: 
at 48 h and 72 h aft er induction of DOMS. 
Participants reported decreased pain 
immediately aft er intervention (T48 - T49 and 
T72 - T73), regardless of whether active or 
sham US was used. In contrast, participants 
did not report decreased pain over the 23 h 
between interventions (T49 - T72), showing 
that changes in pain over the intervention 
periods cannot be attributed to spontaneous 
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Fig. 4. Changes in elbow ROM over time. (ROM = range of movement; US = ultrasound.)
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resolution of DOMS. These results indicate 
that active and sham US treatments were 
both equally effective in reducing pain.
Changes in ROM were also unaffected by 
the nature of the intervention. Participants 
showed a loss of ROM over the first 48 h, to 
be expected after the induction of DOMS. 
They showed a recovery of some ROM during 
the first intervention and no significant 
changes thereafter, suggesting that the two 
interventions were equally effective 48 h after 
DOMS induction. These results also revealed 
a statistically significant difference in recovery 
pattern between sham- and active-treated 
groups between interventions (T49 - T72), but the 
difference was too small to be clinically relevant. 
The comparable efficacy of active US and 
sham US for decreasing pain and improving 
ROM when applied to opposite arms of the 
same participant suggests a mechanism that 
is systemic rather than local. 
Other studies demonstrating a strong 
placebo effect of US
Our results corroborate those of Hashish et 
al.,[12] who found sham US to have comparable 
or better effects than active US for pain and 
inflammation. In fact, the efficacy of US for 
musculoskeletal disorders has been reviewed 
and subjected to meta-analysis.[13] Again, 
the results indicated that active US is not 
appreciably superior to sham US in multiple 
indicators of recovery, including pain and 
swelling.
However, the findings are not entirely unequi-
vocal: some studies still contradict this idea. 
Two out of ten papers reviewed by Robertson et 
al.[2] showed that active US was more beneficial 
than sham US for the treatment of soft-tissue 
injuries; however, only one of these two studies 
used pain as an outcome.
The available evidence suggests that any 
positive therapeutic effect of US treatment 
for pain lies in its placebo value.
How placebos cause analgesia
The placebo effect is driven by both opioid and 
non-opioid mechanisms.[14] When a subject 
anticipates that pain will be relieved, the endo-
genous opioid system is activated, causing a 
powerful analgesic effect. This effect can be 
blocked by naloxone.[3] The placebo effect 
can also be induced by classic conditioning 
when pain reduction is not expected: a 
conditioned response is first set up by 
repeated administration of an inert substance 
together with an exogenous opioid. After this 
administration, the inert substance alone will 
induce analgesia.[3] This conditioned response 
is only partly blocked by naloxone, indicating 
that it works via a non-opioid mechanism.[3]
The opioid-driven component of 
placebo analgesia acts via descending pain-
modulating pathways, involving the rostral 
anterior cingulate cortex, orbitofrontal 
cortex, peri-aqueductal grey matter, pons 
and medulla.[15] These pathways use opioids 
to increase inhibition at the dorsal horn of 
the spinal cord. This reduces the amount 
of nociceptive signal reaching the brain. 
Endogenous opioids also seem to reduce 
inflammatory pain in peripheral tissues. 
Cholecystokinin (CCK) antagonises this 
entire opioid-mediated process, which 
corresponds with CCK’s known role in states 
of anxiety: CCK may increase pain when 
subjects anticipate negative outcomes.[3]
The anticipation that underpins opioid-
driven placebo analgesia is thought to 
depend heavily on psychosocial context. 
The presence of a therapist, the ritual of 
giving a treatment and the visible presence 
of therapeutic equipment may influence it.[3] 
US fits this model: it is a ‘hands-on’ therapy 
that requires a therapist to be actively 
involved throughout the treatment. 
In this study, US was delivered for 7 min 
with the US transducer head visible to the 
participants. The information sheet was read 
to participants before the intervention to 
reduce expectations regarding the efficacy of 
US therapy (‘Ultrasound is an electrotherapy 
modality that is commonly used by physio-
therapists during treatment sessions. How-
ever, there is limited evidence to support its 
effectiveness in the treatment of DOMS. In this 
study, the effectiveness of a non-thermal dose 
of ultrasound on DOMS will be investigated 
with the aim of increasing the evidence base 
for the therapeutic use of ultrasound’), but 
in other respects the psychosocial context 
was typical of a therapeutic situation. The 
presence of a therapist and provision of 
apparent therapy may be enough to overrule 
a neutral information sheet, thus creating an 
overall expectation of improvement. Further 
expectation may have been generated by the 
fact that the participants in the study were 
physiotherapy students who had been trained 
to use US. Although their education and 
training included critical, evidence-based 
material on the efficacy of US, simply including 
the modality in the curriculum may have 
engendered a belief that it works. Anticipation 
of a positive outcome would cause an opioid-
driven placebo response and reduce pain.[16] 
Implications for practice
The ethical considerations arising from 
studies such as this one have caused some 
controversy. Is it acceptable to prescribe 
placebo treatments to patients? The benefits 
of placebo-induced analgesia have been 
well documented,[14] so the conflict revolves 
Table 1. Pain reported on the MPQ, by intervention 
Active US arms, mean (SD) Sham US arms, mean (SD)
T48 6.73 (3.52) 7.40 (6.00)
T49 5.47 (3.16) 5.40 (5.38)
T72 5.13 (5.03) 4.53 (4.09)
T73 3.40 (2.97) 2.80 (3.08)
MPQ = McGill Pain Questionnaire; US = ultrasound; SD = standard deviation.
Table 2. ROM, by intervention
Active US arms, mean (SD) Sham US arms, mean (SD)
Baseline 145.27 (5.80) 144.40 (6.00)
T48 132.87 (9.42) 135.33 (6.39)
T49 136.73 (9.13) 138.20 (5.92)
T72 134.20 (12.16) 139.53 (5.71)
T73 135.53 (12.41) 140.53 (5.08)
ROM = range of movement; US = ultrasound; SD = standard deviation.
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around issues of truthfulness and a patient’s autonomy rather than 
the efficacy of the intervention. Deception may undermine the trust 
that is so important in a good patient-therapist relationship, and 
compromise the principles of informed consent. However, deception 
may not be obligatory, because the therapeutic ritual itself is thought 
to cause the placebo effect.[14] The power of the therapeutic context 
has repeatedly been demonstrated in comparisons between hidden 
and open administration of analgesics: analgesia that is administered 
openly has a far more powerful effect than the same medication given 
covertly.[3] What has not yet been well investigated is whether the 
therapeutic context alone can produce adequate analgesia without a 
specific therapy. However, medical professionals are well placed to 
use listening, empathy and patient-centred communication so as to 
encourage patients to expect positive outcomes. Miller and Colloca[14] 
argue that it is not necessary to use deception when explaining 
treatments that are known to be strongly placebo driven. They suggest 
that a therapist should explain to the patient that studies have found 
both the active and sham modalities to produce notable and equal 
improvements. The point is that it doesn’t matter which version of 
intervention the patient receives, as long as they receive one. To be 
acceptable, this explanation needs to be based on good evidence that 
sham and active treatments are equally helpful.
Strengths and limitations
In this study, each participant acted as her own control. This was a 
notable advantage of the design. This, together with the double blinding, 
ensured that the centrally controlled, systemic placebo response would 
be induced equally in both the active US and sham US arms, while 
local treatment (active US effects) would occur in the active US arm 
only. The symptoms of DOMS are known to differ between subjects[6] 
and the subjective experience of pain cannot be compared accurately 
between different people. Differences in symptoms should therefore be 
compared in the same person, as was done here. 
In this study, the timing of administration of US was based on the 
findings of the pilot study, not tailored to each participant. Changes 
in symptoms were not monitored. However, participants in this study 
acted as their own controls. Since it is unlikely that DOMS would 
occur asymmetrically in a single participant, any difference in timing 
should not have influenced the comparisons across time or groups.
Participants’ other activities during the study were not controlled or 
monitored, although participants were asked not to do any strenuous 
physical activity during the experiment. Varying activity levels could 
have had an effect on the level of DOMS symptoms, potentially 
confounding results. Again, marked differences in biceps activity is 
unlikely to have occurred asymmetrically within a single participant.
Whether the improvement in pain is due to the natural resolution 
of symptoms or the placebo effect cannot be ascertained without 
a non-treatment control group. However, the lack of measurable 
improvement during the 23-h period between treatment sessions, 
compared with the significant decrease in pain after each 1-h 
treatment session, suggests that little of the improvement recorded 
after treatment was due to spontaneous resolution.
Conclusion
This study showed that active US (1 Mhz, 0.4 W/cm2, pulsed 1:4) and 
sham US (1 Mhz, 0 W/cm2, pulsed 1:4) therapy produce equivalent 
improvements in pain when used to treat DOMS of the biceps in the 
context of a therapeutic encounter. These results suggest that US does 
reduce pain, but does so via a placebo effect rather than by a local, 
tissue-specific effect. Clinicians should be guided by this knowledge 
when choosing between interventions to reduce patients’ pain.
Further research is required to determine whether or not the thera-
peutic context is sufficient to elicit a placebo effect, even in the absence of 
a specific therapy. However, what is increasingly clear is that nearly every 
specific therapy also has some placebo value. Clinicians can capitalise 
on this placebo value with communication strategies that improve the 
patient’s experience of the therapeutic encounter and encourage the 
patient to expect a positive outcome. Because anxiety interferes with 
the opioid-mediated mechanism of placebo analgesia, we suggest that 
clinicians will also need to recognise and address patients’ anxiety if the 
placebo value is to be harnessed. Capitalising on the placebo value of the 
therapeutic encounter will boost the analgesic efficacy of therapeutic 
interventions and achieve greater benefit for patients.
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